STEVENSON, Md., Feb. 26, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of ReWalk Robotics Ltd. (Nasdaq:RWLK) (ReWalk or the “Company”) common stock issued in connection with ReWalk's initial public offering conducted on or about September 12, 2014 (the “IPO”). Investors who wish to become proactively involved in the litigation have until March 27, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in ReWalk’s IPO on or about September 12, 2014. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Act of 1933 by virtue of the defendants’ failure to disclose in connection with the Company’s initial public offering that ReWalk was unprepared and/or unable to comply with applicable “special controls” requirements or to provide the U.S. Food and Drug Administration (“FDA”) with a post-market surveillance study as required for the Company to maintain ongoing sales of its products.
According to the complaint, following a September 30, 2015 warning letter from the FDA outlining the failure to detail an adequate post-market surveillance plan, which was disclosed to the public by the FDA on February 25, 2016, the value of ReWalk shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in ReWalk’s September 12, 2014 IPO and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers
CATL Stock Hits Record High After Q1 2025 Earnings Surge
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries”
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 



